# OnCo record lymphoma-ev-manufacturing-time-as-a-trial-endpoint (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/lymphoma-ev-manufacturing-time-as-a-trial-endpoint/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "lymphoma-ev-manufacturing-time-as-a-trial-endpoint" ;
  schema:name "Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote"@en ;
  schema:alternateName "Vein-to-vein time as a CAR-T endpoint"@en, "Manufacturing interval in cell therapy trials"@en ;
  schema:description "The best explanation for why one second-line CAR-T trial failed when two succeeded is how long the cells took to make. That interval is almost never a reported endpoint."@en ;
  schema:url <https://onco.cc/ideas/lymphoma-ev-manufacturing-time-as-a-trial-endpoint/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  onco:tag "lymphoma-evidence" ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:drugs <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/> ;
  onco:terms <https://onco.cc/terms/bridging-therapy/>, <https://onco.cc/terms/lymphodepletion/>, <https://onco.cc/terms/lymphoma-tx-car-t-pathway/> ;
  onco:trials <https://onco.cc/trials/belinda/>, <https://onco.cc/trials/zuma-7/>, <https://onco.cc/trials/transform/>, <https://onco.cc/trials/transcend-nhl-001/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/>, <https://onco.cc/bottlenecks/b-trial-design/>, <https://onco.cc/bottlenecks/b-real-world-evidence/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-belinda-tisagenlecleucel-second-line-nejm-2022/>, <https://onco.cc/key-papers/paper-transcend-nhl-001-liso-cel-lancet-2020/>, <https://onco.cc/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/> .